Press release
Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Discover the latest drugs and treatment options in the Ischemic Stroke Pipeline. Dive into DelveInsight's comprehensive report today! @ Ischemic Stroke Pipeline Outlook [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Ischemic Stroke Pipeline Report
* On 28 August 2025, Pharmazz Inc . announced a phase II study was also conducted in patients with acute ischemic stroke where sovateltide demonstrated significant improvement when compared to standard of care (CTRI/2017/11/010654, NCT04046484). A recent phase III study conducted in patients of acute ischemic stroke demonstrated improved favorable functional and neurological outcome at 3 months compared to standard of care (CTRI/2019/09/021373, NCT04047563).
* On 26 August 2025, Shionogi conducted a study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS). This study consists of 2 cohorts, Cohort A and Cohort B. Cohort A (redasemtide or placebo) will enroll participants who are ineligible for systemic thrombolysis and/or mechanical recanalization therapy. Cohort B (redasemtide or placebo) will enroll participants who are eligible to receive or who have received systemic thrombolysis and/or mechanical recanalization therapy as standard of care.
* DelveInsight's Ischemic Stroke pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Ischemic Stroke treatment.
* The leading Ischemic Stroke Companies such as Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Promising Ischemic Stroke Pipeline Therapies such as Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
Stay ahead with the most recent pipeline outlook for Ischemic Stroke. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Ischemic Stroke Treatment Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ischemic Stroke Emerging Drugs Profile
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
Milvexian (BMS-986177) (Factor XIa) is an investigational anticoagulant compound. Factor XIa (FXIa) plays a key role in the activation and amplification of the coagulation cascade via the intrinsic pathway. A small study of Hemophilia C patients showed a lower risk of stroke. The drug is being developed by Bristol-Myers Squibb in collaboration with Johnson & Johnson. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke.
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. In the nonhuman primate MCAO/R model, the treatment of XY03-EA for 3 weeks could significantly inhibit the NDS progression rate and indicate a positive trend to reduce the infarct volume in a dose-dependent way. Mechanistically, XY03-EA inhibited ROS-dependent autophagy activation and thereby protected the PC-12 cells from the autophagic cell death induced by OGD/R. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
* NONO-42: NoNO Inc.
NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Of the 650,000 people experiencing an acute ischemic stroke treated annually in US hospitals, approximately 10% receive a thrombolytic, which may reduce the applicability of nerinetide. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase II stage of its development for the treatment of acute ischemic stroke.
* hNPC01: Hopstem Biotechnology
hNPC01 refers to a novel cell therapy utilizing human induced pluripotent stem cell (iPSC)-derived human forebrain neural progenitor cells aimed at treating ischemic stroke. This therapy is particularly significant as it represents the first iPSC-derived product to receive FDA Investigational New Drug (IND) clearance for stroke treatment. Currently, the drug is in Phase I stage of its development for the treatment of acute ischemic stroke.
The Ischemic Stroke Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
* Ischemic Stroke Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market
Explore groundbreaking therapies and clinical trials in the Ischemic Stroke Pipeline. Access DelveInsight's detailed report now! @ New Ischemic Stroke Drugs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Ischemic Stroke Companies
Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Ischemic Stroke Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Ischemic Stroke Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Ischemic Stroke Market Drivers and Barriers [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Ischemic Stroke Pipeline Report
* Coverage- Global
* Ischemic Stroke Companies- Genentech, Supergene, Tasly Pharmaceutical, Pharmazz, GNT Pharma, NoNO, Angde Biotech Pharmaceutical, ZZ Biotech, Bristol-Myers Squibb, Athersys, Bayer Healthcare, NuvOx Pharma, Healios, Acticor Biotech, DiaMedica Therapeutics, Moleac, Biogen, Revalesio Corporation, and Shijiazhuang Yiling Pharmaceutical Co and others.
* Ischemic Stroke Pipeline Therapies- Afamelanotide, Neflamapimod, Recombinant human urokinase, Alteplase, Aspirin, Ticagrelor, AX200 (G-CSF), Acetylsalicylic acid (ASA), Sovateltide, NXY-059 and others.
* Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Ischemic Stroke Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Ischemic Stroke Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Ischemic Stroke: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Ischemic Stroke- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* hNPC01: Hopstem Biotechnology
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Ischemic Stroke Key Companies
* Ischemic Stroke Key Products
* Ischemic Stroke- Unmet Needs
* Ischemic Stroke- Market Drivers and Barriers
* Ischemic Stroke- Future Perspectives and Conclusion
* Ischemic Stroke Analyst Views
* Ischemic Stroke Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ischemic-stroke-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ischemic Stroke Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here
News-ID: 4163902 • Views: …
More Releases from ABNewswire
Major depressive disorder Market Outlook 2034 - Clinical Trials, Market Size, Me …
According to DelveInsight, the Major Depressive Disorder Treatment Market Size in the 7MM was approximately USD 7,165 million in 2023.
Major depressive disorder Market Summary
According to DelveInsight, there were ~44 million diagnosed cases of Major Depressive Disorder (MDD) across the 7MM in 2023. The US led the market, valued at ~USD 5.6 billion, projected to grow at a 4.8% CAGR through 2034. Current treatments include VRAYLAR, AUVELITY, SPRAVATO, and REXULTI, with…
Short Bowel Syndrome Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, F …
DelveInsight's, "Short Bowel Syndrome Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Short Bowel Syndrome pipeline landscape. It covers the Short Bowel Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Short Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest…
Sarcopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approva …
DelveInsight's, "Sarcopenia Pipeline Insight 2025" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sarcopenia pipeline landscape. It covers the Sarcopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Sarcopenia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Sarcopenia Research. Learn more about our…
Psoriasis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approval …
DelveInsight's "Psoriasis Pipeline Insight, 2025" report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Psoriasis Research. Learn more…
More Releases for Ischemic
Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: A …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Acute Ischemic Stroke Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for acute ischemic stroke therapeutics has seen appreciable growth lately. Its expansion is expected to proceed from $9.24 billion in 2024 to about $10.12 billion in 2025, manifesting a compound…
Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: K …
The Acute Ischemic Stroke Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acute Ischemic Stroke Therapeutics Market Size During the Forecast Period?
The acute ischemic stroke therapeutics market has experienced significant growth in recent years. It is projected to rise from…
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke…
Ischemic Cardiomyopathy Treatment Market Growth, Challenges, Opportunities and E …
"The new report has been added by qyresearch.com to provide detailed insight into the global Ischemic Cardiomyopathy Treatment market. The study will help to get a better understanding about the Ischemic Cardiomyopathy Treatment industry competitors, a channel for the distribution, Ischemic Cardiomyopathy Treatment growth potential, potentially disruptive trends, Ischemic Cardiomyopathy Treatment industry product innovations, market size value/volume (regional/country level, Ischemic Cardiomyopathy Treatment industry segments), market share of top players/products.
Due to…
Transient Ischemic Attack Market Forecast by 2025
Recent Transient Ischemic Attack market research and the current scenario as well as future market potential of "Global Transient Ischemic Attack Market Professional Survey Report 2020". The Transient Ischemic Attack Market comprehensively describes the market and prognosticates it to describe a highly illustrious growth during the anticipated years. The report offers an in-depth analysis of current and future Transient Ischemic Attack Market outlook across the globe. The report is projected…
Acute Ischemic Stroke Diagnosis And Treatment Market : Increased Usage of Advanc …
A recent report on global acute ischemic stroke diagnosis and treatment market has been analyzed by Transparency Market Research (TMR). The market for acute ischemic stroke diagnosis and treatment is expected to increase during the forecast period with the increasing incidence of strokes, technically advanced techniques, and successful results through treatment surgeries. Technological advancement and constant efforts made by leading companies are providing improved treatments for people suffering from ischemic…
